Mindfulness to Enhance Quality of Life and Support Advance Care Planning (MEANING)
10 de agosto de 2020 atualizado por: Shelley Johns, Indiana University
Mindfulness to Enhance Quality of Life and Support Advance Care Planning (MEANING): A Randomized Controlled Pilot Trial for Adults With Metastatic Cancer and Their Family Caregivers
The MEANING trial is a randomized controlled mixed methods pilot designed to compare a novel mindfulness meditation-based intervention (MEANING) to usual care for adults with advanced-stage solid malignancies and their family caregivers.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
Mindfulness meditation practices have reduced emotional distress, avoidant coping, and improved spiritual well-being in adult cancer patients. These beneficial effects may occur through present-moment acceptance of unpleasant thoughts, feelings, and circumstances and adaptive coping through self-awareness, self-regulation, and self-transcendence. Most mindfulness trials in cancer have focused on early-stage survivors; however, preliminary evidence suggests that mindfulness may help reduce distress in patients with advanced cancer and their family caregivers (FCGs).
Sixty patients with an advanced-stage solid malignancy and their FCGs (60 dyads) will be randomized in equal numbers to receive either the 6-week mindfulness intervention or usual care. Both groups will receive standard cancer care throughout the study period. Dyads randomized to the mindfulness arm will learn mindfulness meditation practices (e.g., body scan, sitting meditation) and mindful communication practices to enhance quality of life, support advance care planning engagement, and improve a variety of secondary outcomes.
The study will use a mixed methods 2-arm randomized design to examine the effects of the mindfulness intervention compared to usual care and seek to explain trial results using insights gleaned from post-intervention qualitative interviews.
Tipo de estudo
Intervencional
Inscrição (Real)
108
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Indiana University
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Sim
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria-Patients
- Patient is at least 18 years of age.
- Patient is at least 3 weeks post-diagnosis of an incurable (locally advanced or metastatic) solid malignancy.
- Patient's attending medical oncologist would not be surprised if the patient died in the next 12 months.
- Patient has not completed a POST form.
- Patient scores ≥ 7 on the Mini-Mental Adjustment to Cancer cognitive avoidance subscale.
- Patient is willing and able to consent and travel to the class location for 6 weekly 2-hour sessions.
- Patient has a family member or close friend eligible and interested in participating in the study.
- Patient has adequate English fluency for completion of data collection
Inclusion Criteria-Family Care Givers (FCG)
- FCG is at least 18 years of age.
- FCG has been invited to participate in the trial with a patient who meets eligibility criteria above.
- FCG is willing and able to consent and travel to the class location for 6 weekly 2-hour sessions.
- FCG has adequate English fluency for completion of data collection
Exclusion Criteria-Patients
- Patient reports a score of > 2 on the Activities and Function item from the Patient Generated Subjective Global Assessment91 (PG-SGA; the patient-reported version of the Eastern Cooperative Oncology Group score).
- Patient makes 3 or more errors on a validated 6-item cognitive screener or exhibits significant psychiatric or cognitive impairment (e.g., dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation.
- Currently receiving hospice care (patients who enroll in hospice during the trial will have the option of continuing trial participation).
Exclusion Criteria-FCGs
• FCG exhibits significant psychiatric or cognitive impairment (e.g., dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: Usual Care
Participants assigned to Usual Care will continue to receive standard care from their oncology team, including access to supportive care from oncology social workers.
At the end of the study, usual care dyads will receive a packet of informational materials on mindfulness meditation, receive a CD with 5 mindfulness meditation practices, and meet with the study interventionist for guidance on how to use the materials and mindfulness recordings to their advantage in coping with cancer-related challenges.
|
|
|
Comparador Ativo: Mindfulness
The Mindfulness intervention will consist of six 2-hour sessions that will include guided mindfulness practices, didactics, and group discussion.
The course curriculum is modeled on the Mindfulness-Based Stress Reduction program which involves intensive experiential training of participants in secular mindfulness meditation practices (i.e., body scan, sitting meditation, gentle hatha yoga with chair adaptations, compassion meditation), with an emphasis on embodying interpersonal mindfulness in dialogue.
|
The Mindfulness intervention sessions are designed to cultivate present-moment awareness in everyday life to facilitate adaptive and non-reactive relating to thoughts, feelings, and bodily sensations.
Participants will be provided with 10-20 minute audio recordings of each of 5 mindfulness practices covered in class, recorded in the facilitator's voice.
Participants will be encouraged to practice mindfulness at home 10-20 minutes per day, 6 days per week.
Participants will be provided with weekly diaries on which to record type and amount of home practice of mindfulness skills.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from baseline in quality of life (QoL) for Patients
Prazo: Baseline, 6 weeks, and 10 weeks
|
QoL for patients will be assessed with the McGill Quality of Life Inventory.
|
Baseline, 6 weeks, and 10 weeks
|
|
Change from baseline in quality of life (QoL) for Family Caregivers
Prazo: Baseline, 6 weeks, and 10 weeks
|
QoL for family caregivers will be assessed with the Caregiver Quality of Life - Cancer scale (CQoLC).
|
Baseline, 6 weeks, and 10 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from baseline in advance care planning (ACP) stage of change
Prazo: Baseline, 6 weeks, and 10 weeks
|
ACP stage of change will be assessed by a measure modified from Fried et.
al assessing stage of change for 3 advance care planning behaviors (completing a living will, medical power of attorney form, or POLST form; patient only measure).
|
Baseline, 6 weeks, and 10 weeks
|
|
Change from baseline in advance care planning (ACP) engagement
Prazo: Baseline, 6 weeks, and 10 weeks
|
ACP engagement (self-efficacy, readiness) will be measured using 2 subscales of the Advance Care Planning Engagement Survey (patient only measure).
|
Baseline, 6 weeks, and 10 weeks
|
|
Change from baseline in caregiver burden
Prazo: Baseline, 6 weeks, and 10 weeks
|
Caregiver burden will be measured using the Zarit Burden Interview (family caregiver measure only)
|
Baseline, 6 weeks, and 10 weeks
|
|
Change from baseline in avoidant coping
Prazo: Baseline, 6 weeks, and 10 weeks
|
Avoidant coping will be assessed using the Mini-MAC Cognitive Avoidance subscale
|
Baseline, 6 weeks, and 10 weeks
|
|
Change from baseline in avoidant coping
Prazo: Baseline, 6 weeks, and 10 weeks
|
Avoidant coping will be assessed using the Brief COPE Self-Distraction, Denial, and Behavioral Disengagement subscales
|
Baseline, 6 weeks, and 10 weeks
|
|
Change from baseline in depressive symptoms
Prazo: Baseline, 6 weeks, and 10 weeks
|
Depressive symptoms will be assessed using the PHQ-8
|
Baseline, 6 weeks, and 10 weeks
|
|
Change from baseline in anxiety
Prazo: Baseline, 6 weeks, and 10 weeks
|
Anxiety will be assessed using the GAD-7
|
Baseline, 6 weeks, and 10 weeks
|
|
Change from baseline in spiritual well-being
Prazo: Baseline, 6 weeks, and 10 weeks
|
Spiritual well-being will be measured using the FACIT-SP.
|
Baseline, 6 weeks, and 10 weeks
|
|
Change from baseline in sleep disturbance
Prazo: Baseline, 6 weeks, and 10 weeks
|
Sleep disturbance will be assessed using the PROMIS Sleep Disturbance.
|
Baseline, 6 weeks, and 10 weeks
|
|
Change from baseline in family communication
Prazo: Baseline, 6 weeks, and 10 weeks
|
Family communication will be assessed using the Social Constraint Scale
|
Baseline, 6 weeks, and 10 weeks
|
|
Change from baseline in interpersonal closeness
Prazo: Baseline, 6 weeks, and 10 weeks
|
Interpersonal closeness will be assessed using the Perceived Interpersonal Closeness Scale.
|
Baseline, 6 weeks, and 10 weeks
|
|
Change from baseline in acceptance of illness
Prazo: Baseline, 6 weeks, and 10 weeks
|
Acceptance of illness will be assessed using the PEACE Scale.
|
Baseline, 6 weeks, and 10 weeks
|
|
Change from baseline in mindfulness
Prazo: Baseline, 6 weeks, and 10 weeks
|
Mindfulness will be assessed using the FFMQ-SF Non-reactivity to Internal Experience and Acting with Awareness subscales.
|
Baseline, 6 weeks, and 10 weeks
|
|
Distress Thermometer
Prazo: Baseline, 6 weeks, and 10 weeks
|
Distress will be assessed using the Distress Thermometer.
|
Baseline, 6 weeks, and 10 weeks
|
|
Intervention satisfaction and helpfulness
Prazo: 6 weeks
|
Satisfaction and helpfulness with the Mindfulness intervention will be assessed using single-item investigator-created 7- and 10-point Likert scales, respectively (Mindfulness group only).
|
6 weeks
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Shelley A Johns, PsyD, Indiana University School of Medicine
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
9 de maio de 2017
Conclusão Primária (Real)
11 de dezembro de 2017
Conclusão do estudo (Real)
11 de dezembro de 2017
Datas de inscrição no estudo
Enviado pela primeira vez
16 de agosto de 2017
Enviado pela primeira vez que atendeu aos critérios de CQ
17 de agosto de 2017
Primeira postagem (Real)
22 de agosto de 2017
Atualizações de registro de estudo
Última Atualização Postada (Real)
12 de agosto de 2020
Última atualização enviada que atendeu aos critérios de controle de qualidade
10 de agosto de 2020
Última verificação
1 de agosto de 2020
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 1702223546
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
INDECISO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Qualidade de vida
-
Indiana UniversityRecrutamentoUltrassom Point of Care (POCUS)Estados Unidos
-
Aalborg UniversityConcluídoUltrassonografia Point of Care (POCUS)Dinamarca
-
Asociacion Española Primera en SaludIntensive Care Unit Pasteur HospitalConcluídoUltrassom Point of CareUruguai
-
Aga Khan UniversityThe Hospital for Sick Children; Grand Challenges CanadaDesconhecidoUltrassom Point of CarePaquistão
-
Medical University of WarsawRecrutamentoUltrassom Point of Care (POCUS) | Hemodynamic Assessment | Bedside UltrasonographyPolônia
-
University of BolognaRecrutamentoHemodiálise | Avaliação de Volume | Ultrassom Point of Care (POCUS)Itália
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute of Mental Health...ConcluídoTransgênero, HIV Continuum of CareEstados Unidos
-
Hospital for Special Surgery, New YorkConcluídoPeptídeo 1 semelhante ao glucagon | Ultrassom Gástrico | Ultrassom Point of CareEstados Unidos, Canadá
-
Johann Wolfgang Goethe University HospitalConcluídoFormação de Coágulos e Agregação de Plaquetas em Testes Point of CareAlemanha
-
Queens College, The City University of New YorkRecrutamentoPublicação de artigos submetidos ao American Journal of Public HealthEstados Unidos